Synonym
D-3112; D 3112; D3112; WY-48624; WY48624; WY 48624; Enciprazine.
IUPAC/Chemical Name
1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(3,4,5-trimethoxyphenoxy)propan-2-ol
InChi Key
KSQCNASWXSCJTD-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H32N2O6/c1-27-20-8-6-5-7-19(20)25-11-9-24(10-12-25)15-17(26)16-31-18-13-21(28-2)23(30-4)22(14-18)29-3/h5-8,13-14,17,26H,9-12,15-16H2,1-4H3
SMILES Code
OC(COC1=CC(OC)=C(OC)C(OC)=C1)CN2CCN(C3=CC=CC=C3OC)CC2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
432.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Matheson GK, Knowles A, Gage D, Michel C, Guthrie D, Bauer C, Blackbourne J, Weinzapfel D. Modification of hypothalamic-pituitary-adrenocortical activity by serotonergic agents in the rat. Pharmacology. 1997 Aug;55(2):59-65. PubMed PMID: 9323305.
2: Scatina JA, Lockhead SR, Cayen MN, Sisenwine SF. Metabolic disposition of enciprazine, a non-benzodiazepine anxiolytic drug, in rat, dog and man. Xenobiotica. 1991 Dec;21(12):1591-604. PubMed PMID: 1686125.
3: Engel J, Fleischhauer I, Jakovlev V, Kleemann A, Kutscher B, Nickel B, Rauer H, Werner U, Szelenyi I, Johanson CE, et al. Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds. J Med Chem. 1990 Nov;33(11):2976-81. PubMed PMID: 1977910.
4: Scheibe G, Grohmann R, Buchheim P. Pilot study on the therapeutic efficacy, clinical safety, and dosage finding of enciprazine in out-patients with anxious and anxious-depressive syndromes. Arzneimittelforschung. 1990 Jun;40(6):644-6. PubMed PMID: 2204343.
5: Schweizer E, Rickels K, Csanalosi I, London J, Turner D. A placebo-controlled study of enciprazine in the treatment of generalized anxiety disorder: a preliminary report. Psychopharmacol Bull. 1990;26(2):215-7. PubMed PMID: 2236459.
6: Nickel B, Szelenyi I. Comparison of changes in the EEG of freely moving rats induced by enciprazine, buspirone and diazepam. Neuropharmacology. 1989 Aug;28(8):799-803. PubMed PMID: 2571102.
7: Linden M, Helmchen H, Müller-Oerlinghausen B. Early phase-II semi double-blind study of the new alkaline propanolamine derivative enciprazine (short communication). Arzneimittelforschung. 1988 Jun;38(6):814-6. PubMed PMID: 3178922.
